Last reviewed · How we verify
NCT04612907: Hypo-M1
Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer
NA trial testing Moderate hypo-fractionation in Prostate Cancer in 420 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | Umeå University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 420 |
| Start date | 31 October 2022 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 September 2032 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Moderate hypo-fractionation
- Ultra-hypo-fractionation
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Radiotherapy Side Effect — all drugs for Radiotherapy Side Effect →
- Metastatic Cancer — all drugs for Metastatic Cancer →
Sponsor
Umeå University
Who can join
18 and older, male only, with Prostate Cancer or Radiotherapy Side Effect. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04612907
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Umeå University trials
Trials by the same sponsor.
- NCT07407946 — Blended Trauma-Focused Cognitive Behavioral Therapy With Compassion · NA · recruiting
- NCT07346820 — VDJ-recombination of the B-cell Receptor Following Hematopoietic Stem Cell Transplantation · not yet recruiting
- NCT07417358 — Single-Stapled Technique for Colorectal Anastomosis · recruiting
- NCT07316426 — Preoptimisation in Ventral Hernia Surgery · NA · recruiting
- NCT07170722 — Sub-threshold DRG Stimulation vs Sham in Established Responders · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04612907 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Umeå University
- Last refreshed: 28 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04612907.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing